2012
Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).
deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.Peer-Reviewed Original ResearchStage IA/IBDisease-free survivalUterine serous cancerIIIA/IIIBIVA/IVBIA/IBUSC patientsPrognostic factorsMyometrial invasionLargest single-institution experienceWhole-pelvis radiation therapyLymph node involvementPlatinum-based chemotherapySingle institution experienceIndependent prognostic factorLymph node metastasisTreatment-related outcomesUterine cancer deathsBetter OSII-IVBIB diseaseNode involvementSurgical debulkingSerous cancerShorter OS
2011
Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression. Journal Of Oncology 2011, 2011: 628084. PMID: 22187554, PMCID: PMC3236522, DOI: 10.1155/2011/628084.Peer-Reviewed Original ResearchProgression-free survivalClear cell cancerOverall survivalCell cancerUterine cancerAggressive histologic subtypeRetrospective chart reviewSingle institution experiencePlatinum-based chemotherapyAdvanced-stage patientsSingle academic institutionAdjuvant therapyChart reviewFIGO stageWorse survivalUterine corpusClinicopathologic featuresHistologic subtypePoor prognosisTreatment regimensExcellent survivalDisease progressionTreatment strategiesClinicopathologic parametersInnovative therapiesMicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncology 2011, 122: 366-371. PMID: 21571355, DOI: 10.1016/j.ygyno.2011.04.033.Peer-Reviewed Original ResearchConceptsLow let-7aDisease progressionLet-7aSurvival analysisEpithelial ovarian cancer patientsPlatinum-based chemotherapyOvarian cancer managementOvarian cancer patientsAddition of paclitaxelType of treatmentLet-7a expressionOvarian cancer resistanceOverall survivalDifferent chemotherapyEOC patientsPatient survivalSurvival outcomesDisease stageOvarian tumorsCancer patientsTumor gradeDisease outcomeCancer managementBetter survivalEOC survival